Autopsy report · NCT03930771

Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas

“the study had a low accrual rate”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 4 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Weill Medical College of Cornell University

Sponsor type

University, hospital or other

Conditions

Recurrent Pituitary Adenomas

Interventions

Capecitabine; Temozolomide

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• Pre-operative Zoledronate in Triple Negative Breast Cancer
  “The study stopped prematurely due to the low accrual rate” (88% match in meaning)
• Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
  “The study was closed for slow accrual” (84% match in meaning)
• Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
  “Study was closed to low accrual.” (82% match in meaning)
• S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery
  “This study was closed early due to poor accrual” (81% match in meaning)
• Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
  “accrual was slow and sporadic so the study was closed” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.